Immuneering Corp (IMRX) insider trading
Every open-market stock purchase and sale by Immuneering Corp executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders bought $320K over the last 12 months (8 buys).
- Last insider buy: Benjamin J. Zeskind (CEO), $10.9K, 3 months ago.
Last 12 months: insiders bought $320K (8 buys) and sold $0 (0 sales). Last close $4.64 on Jul 17, 2026.
Recent IMRX insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Jul 16, 2026 | Andrew Gengos (CFO) | Bought (not open market) | — |
| Jun 23, 2026 | Benjamin J. Zeskind (CEO) | Bought | $10.9K |
| Jun 15, 2026 | Brett Matthew Hall (C-suite exec) | Bought | $25K |
| Jun 11, 2026 | Peter Feinberg (Director) | Bought (not open market) | — |
| Jun 11, 2026 | Laurie Keating (Director) | Bought (not open market) | — |
| Jun 11, 2026 | Robert J Carpenter (Director) | Bought (not open market) | — |
| Jun 11, 2026 | Diana Hausman (Director) | Bought (not open market) | — |
| Jun 11, 2026 | Thomas J. Schall (Director) | Bought (not open market) | — |
| Mar 13, 2026 | Leah R Neufeld (C-suite exec) | Bought (not open market) | $15.6K |
| Feb 3, 2026 | Harold Eugene Brakewood (C-suite exec) | Bought (not open market) | — |
| Feb 3, 2026 | Brett Matthew Hall (C-suite exec) | Bought (not open market) | — |
| Feb 3, 2026 | Michael Bookman (C-suite exec) | Bought (not open market) | — |
| Feb 3, 2026 | Leah R Neufeld (C-suite exec) | Bought (not open market) | — |
| Feb 3, 2026 | Mallory Morales (C-suite exec) | Bought (not open market) | — |
| Feb 3, 2026 | Igor Matushansky (C-suite exec) | Bought (not open market) | — |
| Feb 3, 2026 | Benjamin J. Zeskind (CEO) | Bought (not open market) | — |
| Jan 16, 2026 | Harold Eugene Brakewood (C-suite exec) | Bought | $25K |
| Jan 15, 2026 | Thomas J. Schall (Director) | Bought | $101K |
| Jan 15, 2026 | Brett Matthew Hall (C-suite exec) | Bought | $10.5K |
| Jan 13, 2026 | Leah R Neufeld (C-suite exec) | Bought | $10.9K |
| Jan 12, 2026 | Peter Feinberg (Director) | Bought | $86.9K |
| Jan 1, 2026 | Peter Feinberg (Director) | Bought (not open market) | — |
| Jan 1, 2026 | Laurie Keating (Director) | Bought (not open market) | — |
| Oct 3, 2025 | Peter Feinberg (Director) | Bought | $50K |
Who's trading IMRX
- Andrew Gengos, CFO: other filings, last Jul 16, 2026
- Benjamin J. Zeskind, CEO: bought $10.9K (1 buy), last Jun 23, 2026
- Brett Matthew Hall, C-suite exec: bought $35.5K (2 buys), last Jun 15, 2026
- Diana Hausman, Director: other filings, last Jun 11, 2026
- Robert J Carpenter, Director: other filings, last Jun 11, 2026
- Peter Feinberg, Director: bought $137K (2 buys), last Jun 11, 2026
- Laurie Keating, Director: other filings, last Jun 11, 2026
- Thomas J. Schall, Director: bought $101K (1 buy), last Jun 11, 2026
- Leah R Neufeld, C-suite exec: bought $10.9K (1 buy), last Mar 13, 2026
- Michael Bookman, C-suite exec: other filings, last Feb 3, 2026
- Igor Matushansky, C-suite exec: other filings, last Feb 3, 2026
- Harold Eugene Brakewood, C-suite exec: bought $25K (1 buy), last Feb 3, 2026
- Mallory Morales, C-suite exec: other filings, last Feb 3, 2026
Get free alerts when an insider at Immuneering Corp files a new trade →